Standout Papers

Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes 2013 2026 2017 2021 1.8k
  1. Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes (2013)
    William B. White, Christopher P. Cannon et al. New England Journal of Medicine
  2. Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial (2015)
    Faı̈ez Zannad, Christopher P. Cannon et al. The Lancet

Immediate Impact

5 from Science/Nature 115 standout
Sub-graph 1 of 15

Citing Papers

Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss Among Adults Without Diabetes
2025 Standout
A comprehensive spatio-cellular map of the human hypothalamus
2025 StandoutNature
1 intermediate paper

Works of P. Fleck being referenced

Efficacy and safety of glucagon‐like peptide‐1/glucagon receptor co‐agonist JNJ‐64565111 in individuals with obesity without type 2 diabetes mellitus: A randomized dose‐ranging study
2021

Author Peers

Author Last Decade Papers Cites
P. Fleck 4198 1592 1435 38 4.6k
Peter P. Stein 4226 1722 1609 27 4.7k
Hans‐Juergen Woerle 4004 1616 1866 59 4.3k
Peter Öhman 4912 1949 1594 32 5.4k
Klaus A. Dugi 2880 1401 1526 71 4.3k
M. Angelyn Bethel 4201 1618 1452 39 4.9k
Craig Wilson 2901 1103 947 27 3.2k
S. Dejager 4282 1654 2577 93 5.9k
Mark Kipnes 2815 1199 1291 56 4.1k
Debora Williams‐Herman 3135 1317 1310 46 3.9k
Jaime A. Davidson 6384 2352 2612 97 7.9k

All Works

Loading papers...

Rankless by CCL
2026